Background: Microcytic erythrocytosis is an underrecognized and underevaluated complete blood count (CBC) finding. The literature pertaining to the determination of its etiology specifically by hemoglobin variant analysis is limited.
hemoglobin (HGB), hematocrit (HCT), mean red cell volume (MCV), mean hemoglobin content (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), platelet (PLT) count, and mean platelet volume (MPV). [1] [2] [3] Clinical relevance of many of these CBC parameters alone and/or in various combinations is well established and appropriately utilized by clinicians. [4] [5] [6] [7] [8] [9] [10] Nonetheless, clinical relevance of the results of some of the CBC parameters remains poorly understood and consequently inadequately appreciated. Microcytic erythrocytosis, characterized by decreased MCV and increased RBC count, is a common but one of such underrecognized and underevaluated CBC findings, especially in nonanemic patients. In our laboratory, which performs approximately 700 CBCs a day, the finding of microcytic erythrocytosis is noted on average in about 8 cases a day, 3 of which represent new cases per day amounting to nearly 1100 cases annually. Based on our laboratory data, only a small fraction of these (approximately 4%), however, get investigated specifically for determining the etiology of microcytic erythrocytosis by hemoglobin variant analysis (HVA). The most common cause of decreased MCV worldwide is iron deficiency. However, other conditions such as thalassemias, some hemoglobinopathies, lead poisoning, some cases of anemia of chronic disease/inflammation/infection, and sideroblastic anemia are also associated with decreased MCV. [5] [6] [7] In contrast, increased RBC count is often associated with polycythemia (primary and secondary) and infrequently with uncommon hemoglobinopathies associated with high oxygen affinity. 11 The latter conditions are, however, not typically associated with decreased MCV. Although the etiology underlying the combined findings of decreased MCV and increased RBC count can be multifactorial, we hypothesized that thalassemias and select hemoglobinopathies are probably the common contributors. To test our hypothesis, we evaluated the results of HVA performed in patients revealing microcytic erythrocytosis with or without accompanying anemia on CBC and determined the types and relative frequencies of these hemoglobin-associated disorders among such cases.
Materials and Methods
The study, as approved by the Institutional Review Board of Thomas Jefferson University, included review of the results of CBC and HVA from the clinical laboratory records (CLRs) and information on age, gender, and ethnicity of patients from electronic medical record (EMR). The study population included all patients who came to the attention of a pathologist over a period of 2 years in the way of blood smear review because their CBCs revealed microcytic erythrocytosis. Based on our laboratory's pre-established policy, the blood smear review by a pathologist was ordered reflexively for microcytic erythrocytosis whenever the clinician had ordered a CBC with differential (Diff) but not if the order was for CBC without Diff. For cost-containment reasons, our laboratory policy allowed and the clinicians routinely ordered CBC without Diff more frequently than the CBC with Diff in an estimated ratio of 1.5:1.0. An order for a CBC without Diff understandably did not get a blood smear made. The CBC data were generated using EDTAanticoagulated blood specimens on an automated hematology analyzer (XE-5000, Sysmex America, Mundelein, IL), which was calibrated and quality controlled as per manufacturer's instructions. 12 The HVA was performed on the leftover CBC specimen, if available, whenever its result was not found in the CLR and EMR. To our surprise, we had to resort to performing HVA on leftover specimens in most cases (96% of study patients). Bio-Rad Variant, a high-pressure liquid chromatography (HPLC) system from Bio-Rad laboratories (Hercules, CA) was utilized to perform the HVA. Manufacturer's instructions 13 were followed for the purpose of quality control. The resolution software used by this analyzer was Primus Variant (PVS99, ultra 2 resolution). An HPLC pattern was considered normal when it comprised over 95% hemoglobin A, 2.0%-3.5% hemoglobin A 2 , and less than 2% hemoglobin F. The results of the HPLC were reviewed and interpreted under the guidance of a board-certified pathologist using a widely accepted publication 14 as a helpful resource for interpretation as needed.
In the study period, we collected CBC and HVA data on a total of 137 patients (50 male and 87 female /uL in men. The age and gender-specific reference ranges shown in Table 1 were used to determine the elevation of the RBC count and decrease in the MCV level for the pediatric patients.
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Results
The pertinent CBC findings of the study patients were as follows: the HGB values ranged from 7.2 to 16.1 g/ dL (median 12.9 g/dL), the MCVs ranged from 55 to 79 fL (median 64 fL), and the RBC counts ranged from 5.2 to 7.5 × 10 6 /uL (median 6.2 × 10 6 /uL). In 74 of the 137 (54.0%) patients, microcytic erythrocytosis was accompanied by anemia based on age and gender-specific reference ranges, which for adults was an HGB level below 12.5 g/dL for female patients and below 14.0 g/dL for male patients. A total of 63 (46.0%) patients had hemoglobin levels within the age and gender-specific reference ranges (12.5-15 g/ dL for adult female patients and 14-17 g/dL for adult male patients).
The results of the HVA were initially categorized into 2 groups based on whether or not the finding of microcytic erythrocytosis was accompanied by anemia and later combined to obtain the overall picture ( Table 2 ).
Elevated levels of hemoglobin A 2 (>3.5%, range 3.6%-5.3%), consistent with the diagnosis of β-thalassemia trait, were observed in 69 of 137 (50.4%) patients. Only 48 of these 69 (72.1%) patients were anemic. δ/β-thalassemia trait, characterized by elevated level of hemoglobin F at 5.5% and decreased A 2 at 1.8%, was diagnosed in 1 (0.7%) patient, who was not anemic. Elevated levels of hemoglobin A 2 in the range of 87.6% to 93.0% by HPLC but confirmed as hemoglobin E by hemoglobin electrophoresis, consistent with the diagnosis of hemoglobin E disease, were noted in 4 (2.9%) patients, all of whom were anemic. Elevated levels of hemoglobin F at 11%, consistent with the diagnosis of hereditary persistence of fetal hemoglobin (HPFH), was None of the patients diagnosed with either HPFH or possible HPFH was anemic. Elevated levels of hemoglobin F in the range of 5.8% to 58.0% and A 2 in the range of 4.0% to 5.0%, consistent with the diagnosis of HPFH with β-thalassemia trait, were noted in 4 (2.9%) patients, 3 of whom were anemic. The diagnosis of δ/β-thalassemia trait with iron deficiency anemia, characterized by elevated hemoglobin F at 3.6%, decreased A 2 at 1.4%, and decreased serum ferritin at 4 ng/mL, decreased serum iron at 14 mcg/dL and increased total iron binding capacity (TIBC) at 492 mcg/dL, was established in 1 (0.7%) patient, who was anemic. Elevated levels of hemoglobin C at 65% and A 2 at 4.6%, consistent with the diagnosis of hemoglobin C/β-thalassemia trait, were recorded in 1 (0.7%) patient, who was also anemic. An elevated level of hemoglobin C at 24%, suggestive of hemoglobin C trait with possible α-thalassemia, was noted in 1 (0.7%) patient, who was not anemic. Combined elevation of the levels of hemoglobin C at 69.9% and F at 27.6%, consistent with the diagnosis of hemoglobin C/HPFH, was seen in 1 (0.7%) patient, who was also not anemic. The presence of an unidentified abnormal hemoglobin along with an increased level of hemoglobin F and a decreased level of hemoglobin A 2 , suggestive of the diagnosis of an unidentified hemoglobinopathy with possible δ/β-thalassemia, was noted in 2 (1.5%) patients, who were not anemic. The results of the HVA of these 2 patients were as follows: case 1: abnormal hemoglobin 25% at retention time of 2.26 minutes, F 5%, A 2 1.6%, and A 68.3%; case 2: abnormal hemoglobin 41.5% at retention time of 1.70 minutes, F 1.9%, A 2 1.4%, and A 55.2%. The diagnosis of hemoglobin S trait combined with possible α and possible β-thalassemia, characterized by hemoglobin S levels in the range of 24.6% to 32.6% and A 2 levels in the range of 3.6% to 4.3%, was entertained in 4 (2.9%) nonanemic patients. Normal HVA pattern was seen in 44 of 137 (32.3%) patients, 17 (38.6%) of whom were anemic. We noted that none of the 13 patients with the diagnosis of either HPFH, possible HPFH, C/possible α-thalassemia, C/HPFH, S/possible α and possible β-thalassemia, or unidentified hemoglobinopathy/possible δ/β-thalassemia was anemic.
In relating the ethnicity of the patients diagnosed with hemoglobin-associated disorders in our diverse patient population, we observed that all 5 patients with the diagnosis of HPFH or possible HPFH, and all patients with compound heterozygous conditions such as C/thalassemia, S/thalassemia, and C/HPFH were of African American ethnicity. Both patients with the diagnosis of an unidentified hemoglobinopathy/δ/β-thalassemia trait were of Asian descent. Among the patients diagnosed with thalassemia trait, about 50% had Mediterranean ancestry, 20% were Asians, and 14% were of African ancestry; the information about the ethnicity of the remaining 16% was not specified in the EMR.
Additional laboratory findings available for our study population from the CLR included the results of (a) red cell morphology evaluation from the peripheral blood smear reviews in all cases and (b) iron studies in a small fraction of cases.
Target cells and basophilic stippling were the 2 most pertinent morphologic findings revealed by the peripheral blood smear reviews. Target cells in the range of occasional to 4+ were seen in the smears of 55 of 93 (59.1%) patients, who had the HVA pattern consistent with the diagnosis of β-thalassemia trait and/or hemoglobinopathy. In contrast, 17 of the 44 (38.6%) patients with normal HVA pattern revealed target cells in the range of occasional to 2+. The grading levels of target cells in the smears of all patients diagnosed with β-thalassemia trait were at either occasional or 1+. The blood smears of 2 of the 69 (2.9%) patients with the diagnosis of β-thalassemia trait also revealed schistocytes that were graded as 1+. The highest level of grading of target cells at 4+ was recorded in the blood smears of 2 patients, 1 with the diagnosis of hemoglobin C/β-thalassemia and 1 case of hemoglobin EE disease. Both of these patients revealed also spherocytes (graded as 1+ and occasional, respectively) in their blood smears. Target cells graded at 3+ were seen only in 1 patient diagnosed with C/HPFH. Basophilic stippling (graded as 1+) was seen in the blood smears of 12 of 93 (12.9%) patients, who had the HVA pattern consistent with the diagnosis of β-thalassemia trait and/or hemoglobinopathy and only 1 of 44 (2.3%) patients, whose HVA pattern was normal. Grading of morphology was based on previously published criteria. 16 The results of iron studies (serum iron, TIBC, and/or ferritin) were available only for 18 of 137 study patients. Of these 18 patients, 8 had normal HVA patterns, and the other 10 had abnormal HVA patterns consistent with the diagnoses of β-thalassemia trait (6 patients), δ/β-thalassemia trait (2 patients, 1 of whom had concomitant iron deficiency), HPFH (1 patient), and C/β-thalassemia trait (1 patient). Among the 8 patients with normal HVA pattern, the findings of iron studies shown in Table 3 were considered consistent with the diagnosis of iron deficiency anemia in 2 (patients 3 and 5) and suggestive of either iron deficiency without anemia or polycythemia vera with iron deficiency (both unconfirmed) in 3 (patients 1, 2, and 7). The other 3 (patients 4, 6, and 8) were anemic, but their serum ferritin levels were within the reference range. Among the 10 patients with abnormal HVA patterns, the findings of iron studies shown also in Table 3 were considered consistent with the individual patient's diagnosis of the hemoglobin-associated disorder in all but 1. This 1 patient was diagnosed with iron deficiency anemia along with the diagnosis of δ/β-thalassemia trait based on the combined results of the iron studies and the HVA.
Discussion
A diagnosis of hemoglobin-associated disorder was established in 93 of 137 (67.9%) patients based on the results of the HVA. Among these, β-thalassemia trait topped the list with 69 (74.2%) cases followed by hemoglobin E disease with 4 (4.3%) cases, possible HPFH with 4 (4.3%) cases, HPFH with 1 (1.1%) case, and 2 (2.2%) cases of δ/β-thalassemia (1 of which had concomitant iron deficiency anemia). The diagnosis of possible HPFH was entertained in 4 patients based on the sole abnormality of mild elevation of hemoglobin F (2.3%-3.1%) by HPLC. No additional clinical or laboratory information was available on these cases. Since HPFH is typically associated with normal MCV and normal RBC count, the microcytosis and erythrocytosis noted in 5 of our study patients with this diagnosis (1 HPFH and 4 possible HPFH) likely represent an associated undiscovered α-thalassemia trait. Since a definitive diagnosis of α-thalassemia requires additional studies such as α/β chain synthesis ratio and/or DNA analysis for mutations, and none were performed or available on our study population, we chose to use the term possible α-thalassemia in the specified cases. Compound heterozygous conditions for either hemoglobinopathies and/or thalassemia(s) comprised 13 cases. Among these, 4 patients were considered to have hemoglobin S trait with possible α-thalassemia and possible β-thalassemia because in each case the HVA revealed hemoglobin S level below 35% (24.6%-32.6%) and elevated A 2 level (3.7%-4.3%). Routinely, the HPLC pattern seen in sickle cell trait consists of ~40% hemoglobin S and ~60% hemoglobin A. Hemoglobin S levels below 35% suggest a possible underlying α thalassemia trait because of the greater affinity of α-globin for normal β globin chain (β) rather than for mutant β globin chain (β s ) found in sickle cells. Based on review of the patients' records in the EMR, none of these 4 patients had received any blood product transfusion at least for the 3 months prior to the HVA analysis. Some literature 17 has shown that sickle cell trait patients without concomitant β-thalassemia can also have mildly elevated levels of hemoglobin A 2 , hence we chose to use also the term possible β-thalassemia in these cases. Unspecified abnormal hemoglobins detected by the HPLC method in 2 cases remain unidentified as no additional analyses had been performed in both cases.
Although target cells and basophilic stippling were noted in the blood smears of patients with the diagnosis of hemoglobin-associated disorder more frequently than in the blood smears of patients with normal HVA pattern, neither of the 2 findings can be considered 100% specific for hemoglobin-associated disorders. In other words, the presence of target cells and/or basophilic stippling is supportive of the diagnosis of a hemoglobin-associated disorder but their absence does not exclude it.
Among the 44 (32.2%) cases with normal HVA pattern by HPLC, 2 had iron deficiency anemia confirmed by iron studies and an additional 3 nonanemic patients were considered likely candidates for unconfirmed iron deficiency without anemia or polycythemia vera with iron deficiency. Hemoglobinopathy with high oxygen affinity was thought of as an alternative diagnostic consideration for the latter 3 cases but was considered unlikely because it is typically associated with normocytic erythrocytosis rather than microcytic erythrocytosis. With the premise that in clinical practice α-thalassemia trait is usually a diagnosis of exclusion, and microcytic erythrocytosis in patients without an underlying etiology is unlikely, it may be inferred that a majority, if not all, of the 44 cases with normal HVA pattern also represent patients with possible α-thalassemia trait. An alternative likely diagnosis for this group of cases could, however, be a combination of β-thalassemia trait and iron deficiency because the latter may mask the elevation of hemoglobin A 2 typically seen in the former. 7, 18, 19 Anemia of chronic disease (ACD) as a possible underlying etiology for 15 anemic cases was considered but is unlikely because ACD often presents with variable degrees of a normocytic anemia 5 with decreased or normal RBC count.
A small fraction of cases of ACD do present with variable degree of microcytic anemia, but that is still associated with decreased or normal RBC count. With all these potential considerations, over 95% of the studied cases of microcytic erythrocytosis may be categorized as having a possible thalassemia trait and/or a hemoglobinopathy.
Even with the recognition of the limitations of the study, small sample size (137 total cases), and lack of confirmatory data in select cases, our findings can be summarized as follows:
1. Thalassemia trait is the most common clinical condition associated with microcytic erythrocytosis, and it includes all forms, ie, β, α, and δ/β. This observation of our study corroborates the previous reports published by Lafferty, et al, 20 and Bessman. 21 Lafferty and associates performed a comprehensive laboratory investigation for thalassemia on 664 patients with MCV <80 fL and established a diagnosis of thalassemia in 361 (54.4%) patients. The corresponding results of our study, with 51.1% of patients being diagnosed with β-thalassemia trait, are very similar.
Bessman evaluated the results of hemoglobin electrophoresis, A 2 quantitation, and iron studies of 35 patients with MCV <70 fL and RBC count above normal, and reported a diagnosis of proven or probable thalassemia trait in 26 (74.3%) patients, polycythemia vera in 4 (11.4%) patients, and secondary polycythemia with coincidental iron deficiency in 5 (14.3%) patients. The most likely contributors to the relatively higher incidence of thalassemia trait in the patient population studied by Bessman are the differences in (a) the level of MCV used to define microcytosis (<70 fL as opposed to <80 fL used by Lafferty JD and associates, and us) and (b) the size of the patient population (35 in contrast to 137 in our study and 664 in the study by Lafferty JD, et al). Whether or not the difference in the ethnicity makeup of the patient populations among the studies also contributed to the observed difference in the incidence of thalassemia trait between the studies cannot be ascertained because neither of the 2 comparable studies provided the related information. 2. Not all thalassemia trait patients present with anemia. Only 69% of the patients with thalassemia trait in our study population were anemic. There is no comparative study with which we can compare this finding. 3. Microcytic erythrocytosis with or without accompanying anemia may be associated with:
(a) Certain hemoglobinopathies such as hemoglobin E disease. Of 137 patients in our study, 4 (2.9%) fell into this category. Of note, all 4 patients presented with anemia. (b) Compound heterozygous conditions such as hemoglobin C trait with β-or α-thalassemia trait, hemoglobin S trait with β-and/or α-thalassemia trait, and HPFH with β-thalassemia trait, among others. 9.5% of the patients in our study fell into this category, and 30% of these were anemic.
Observation 3 is also in agreement with the findings previously published by Lafferty and associates, 20 who reported an incidence of 6.3% for certain hemoglobinopathies (including hemoglobins E, S, C, and others) with or without concomitant thalassemia trait among 664 patients with MCV <80 fL Identification of thalassemia minor/trait as a cause of microcytic erythrocytosis with or without anemia is particularly important for recognizing potential pregnancies at risk of thalassemia major to provide appropriate genetic counseling and to prevent unnecessary iron therapy in patients with microcytic anemia due to thalassemia minor/ trait. We utilized HPLC for hemoglobin variant analysis in our study; however, many other methodologies such as hemoglobin electrophoresis at alkaline and acid pH, capillary electrophoresis, isoelectric focusing, α/β globin chain synthesis ratio, and/or DNA analysis can be utilized for this purpose. Recommendations and/or guidance for selection of method(s) and the extent of analysis are beyond the scope of this study but are available in the published literature. 22, 23 A differential diagnosis of microcytic erythrocytosis should include polycythemia vera and secondary polycythemia with concomitant iron deficiency, in addition to hemoglobin-associated disorders outlined above. Iron deficiency by itself is not typically included in this because, to the best of our knowledge, there is no evidence in the literature in support of associating erythrocytosis with iron deficiency. However, including iron studies in investigating microcytic erythrocytosis may help rule in or out coincidental iron deficiency.
Conclusion
The study findings support our hypothesis that hemoglobin-associated disorders are significant contributors to the combined findings of microcytosis and erythrocytosis. All types of thalassemias and select hemoglobinopathies identified in this study comprise the group of hemoglobin-associated disorders associated with microcytic erythrocytosis. Hemoglobin variant analysis is very useful in the investigation of microcytic erythrocytosis. LM
